Cimetidine Tablets Demand Compression Force and Granule Moisture Control

Compression of cimetidine into 200 mg, 400 mg, and 800 mg tablets requires a wet-granulated intermediate because the free base has insufficient compactability and flow for direct compression on high-speed rotary presses. In a typical intragranular formulation, cimetidine accounts for 60–80% w/w of the core, with microcrystalline cellulose at 10–30% w/w as diluent, sodium starch glycolate at 2–6% w/w as disintegrant, and povidone K30 at 2–4% w/w added as aqueous granulating solution. A high-shear mixer granulator with impeller tip speed 4–8 m/s and chopper speed 1000–3000 rpm is used to form granules, with the endpoint controlled by target power consumption or torque rather than visual inspection. Fluid-bed drying at inlet air temperature 60–70 °C is terminated when granule moisture reaches 1.0–2.5% w/w by loss-on-drying or USP <921> Karl Fischer titration. Dried granules are passed through a conical mill fitted with a 0.8–1.5 mm round-hole screen, then lubricated with magnesium stearate 0.25–0.75% w/w for 3–5 minutes in a bin blender. Tablets are compressed on a rotary press using B-tooling, precompression force 2–5 kN and main compression force 8–20 kN; tablet hardness is held in the 80–150 N range, friability is controlled below 0.8% w/w per USP <1216>, and disintegration is tested per USP <701>. Dissolution is monitored under USP <711> using Apparatus II at 50 rpm in the medium specified by the cimetidine tablet monograph; the acceptance criterion follows the harmonized national monograph or regional regulatory dossier. For 800 mg tablets, the main compression force must be limited to prevent lamination at turret speeds above 60 rpm, because the large tablet mass increases the risk of capping when the granulate is overlubricated or when microcrystalline cellulose is overhydrated during processing. The release package includes ICH Q3D elemental impurity limits and dissolution validation under USP <1092>.

During hard gelatin capsule filling on intermittent dosator machines, the granulated cimetidine blend must show consistent bulk density and flow function, otherwise fill weight variability exceeds USP <905> acceptance criteria before the closure station is reached. A cimetidine capsule formulation containing 200 mg API per size 2 shell or 400 mg per size 0 shell typically requires wet granulation or roller compaction because direct fill blends with more than 60% w/w cimetidine often have angle of repose above 40° and Hausner ratio above 1.40, both outside the range acceptable for consistent dosing. Wet granulation with lactose monohydrate 15–30% w/w, microcrystalline cellulose 10–25% w/w, crospovidone 2–5% w/w, and povidone K30 1–3% w/w produces granules with particle-size distribution 100–850 µm, tapped bulk density 0.45–0.65 g/mL, and loss-on-drying below 2.0% w/w. Capsule filling is performed on a dosator-type or tamping-type machine with target fill weight set by the capsule monograph and in-process mass verification at a frequency of not less than 1 check per 5 minutes; fill weight variation is governed by USP <905> or the regional pharmacopoeial equivalent. Filling rooms are maintained below 60% RH; if ambient RH exceeds 60%, the granulate is held in sealed bins and may require re-drying to avoid moisture-induced flow loss. The terminal product is a hard gelatin capsule containing cimetidine for oral administration. Dissolution testing under USP <711> with the apparatus and medium specified in the cimetidine capsule monograph is used to confirm that the capsule does not introduce a tablet-to-capsule release difference. Because gelatin capsule shells are hygroscopic, storage at 25 °C and 60% RH or below in airtight HDPE containers with desiccant prevents embrittlement and moisture uptake above the release limit. Published data for this specific capsule equipment configuration is limited; therefore, installation qualification and process validation batches are required to define the upper limit of residual granule moisture for each capsule filling line.

Why Does Cimetidine Sachet Granulation Depend on Granule-Size Distribution Rather Than API Assay Alone?

Because sachet filling is volumetric rather than gravimetric, single-dose cimetidine granules are wet granulated to a narrow particle-size distribution; the critical quality attribute is not only cimetidine content but also granule-size distribution and residual moisture. Granulation is performed in a high-shear mixer or fluid-bed granulator with cimetidine concentration 60–80% w/w, mannitol or lactose 10–25% w/w as water-soluble diluent, hydroxypropyl cellulose 1–3% w/w as binder, and croscarmellose sodium 2–4% w/w as disintegrant. A top-spray fluid-bed process with inlet air temperature 55–65 °C may be used to granulate and dry in one unit, with product temperature 30–40 °C; drying is continued until granule moisture is below 2.0% w/w by USP <921>. The dried granulate is screened to target 90% of particles between 180 µm and 850 µm using a vibratory sieve; over-sized particles are passed through a conical mill at 0.8–1.25 mm. This distribution is necessary because fine particles below 90 µm segregate during sachet filling and coarse particles above 1000 µm slow dispersion when the dose is dispersed in water. Sachet filling is carried out on a vertical form-fill-seal machine with auger or volumetric cup filler; fill weight is checked against internal limits tied to USP <905> for single-dose containers. The terminal product is a single-dose sachet containing cimetidine granules for oral suspension or direct administration. Moisture control is the main failure mode: if residual moisture exceeds 2.5% w/w during storage, the granular bed cakes and cimetidine dissolution falls below the monograph Q value; if moisture is below 0.8% w/w, electrostatic charging during sachet filling can cause dose uniformity excursions. Compliance with USP <61> and USP <62> microbial enumeration and USP <1207> package integrity for sachet seals is required.

pH and Filtration Constraints in Cimetidine Hydrochloride Injection

Cimetidine hydrochloride injection is formulated as a sterile solution of cimetidine hydrochloride equivalent to 150 mg/mL cimetidine base in single-dose Type I borosilicate glass vials or ampoules; the pH of the solution is a critical process parameter because the free base precipitates when the solution pH rises above approximately 6.5. The hydrochloride salt is dissolved in Water for Injection at 18–25 °C; dissolution is confirmed by visual clarity and light transmission measurement before volume adjustment. The solution is adjusted with dilute hydrochloric acid or sodium hydroxide to pH 4.0–6.0, then passed through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade PVDF membrane filter. The filtered solution is filled aseptically into Type I borosilicate glass vials; if terminal steam sterilization is used, a cycle such as 121 °C for 15 min is validated by the overkill method with representative load configurations, and sterility is confirmed per USP <71>. Bacterial endotoxin is controlled per USP <85>, particulate matter per USP <788>, and visible particulates per USP <790>. The terminal product is a cimetidine hydrochloride injection for intramuscular or intravenous administration. For intravenous infusion, the injection is diluted with 0.9% sodium chloride injection or 5% glucose injection to a concentration of 15–30 mg/mL cimetidine base; admixture with alkaline solutions such as sodium bicarbonate injection raises pH above the solubility boundary and can cause cloudiness or precipitation. Because the imidazole pKa of cimetidine is near 6.8, the final admixture pH cannot be treated as a simple buffer adjustment without measuring both free base and hydrochloride salt solubility. Published compatibility data for all possible combinations is limited, so physical compatibility must be evaluated by visual inspection and subvisible particle counting per USP <788> before use.

In oral liquid presentations, cimetidine hydrochloride is dissolved in purified water to provide cimetidine base equivalent to 300 mg/5 mL; the solution is adjusted to an acidic pH similar to the injection to maintain solubility and is protected from light. Flavoring and sweetening agents are added only after the API is fully dissolved; the batch is homogenized with a high-shear mixer at 500–1500 rpm for 15–30 min and passed through a 10 µm cartridge filter to remove undissolved excipient agglomerates or foreign matter. The solution is filled into amber glass or PET bottles using a volumetric piston filler, with headspace oxygen minimized by nitrogen purging; fill volume checks are performed at intervals of not more than 15 min during filling. The terminal product is an oral liquid cimetidine preparation. USP <905> uniformity of dosage units is applied to filled bottles based on fill volume checks; stability studies under ICH Q1A(R2) conditions establish shelf life for each packaging configuration. Because the water activity of the liquid is high, the product is protected with preservatives; preservative concentrations are validated by antimicrobial effectiveness testing per USP <51>.